top of page
PAH Patient Evidence Submission Survey: sotatercept
PHA Canada, along with our partners at Scleroderma Ontario, Sclerodermie Quebec, and Foundation HTAPQ, conducted a survey to learn how current pulmonary arterial hypertension (PAH) therapies affect you and your expectations for the new PAH therapy sotatercept. Participants were pulmonary arterial hypertension patients or caregivers residing in Canada.
The survey results were included in the patient/caregiver input we provided to Canada/Quebec’s health technology assessment agencies, CADTH and INESSS.
If you would like more information about the survey or our submissions regarding sotatercept, please get in touch with PHA Canada Executive Director Jamie Myrah at jmyrah@phacanada.ca.
bottom of page